Penetrance is an auditable clinical trial matching engine for precision oncology. It reads every inclusion and exclusion criterion, returns a verdict per line, and points to the exact source span in the patient's notes. Deployed on-prem.
Clinical trials are how oncology moves forward, yet most fail to recruit enough patients in time. The bottleneck is not interest. It is screening: matching one patient's history against pages of dense eligibility criteria is slow, manual, and easy to get wrong.
Screening is done by hand, one chart at a time.
A coordinator reads the full chart, then a protocol's criteria, line by line, ~30 minutes per patient, per trial.
Eligibility lives in unstructured text, both sides.
Stage, biomarkers and labs are scattered across notes. Criteria are dozens of free-text lines with negation and thresholds.
Existing tools return a score, not a reason.
Black-box matching gives a number. A clinician can't see what it read, so they re-check by hand, or skip it.
The cost is not abstract, it is coordinator hours, trials that close under-enrolled, and patients eligible for a study no one had time to check. We have indexed every oncology trial on ClinicalTrials.gov and broken each into structured criteria; the engine runs on that library.
It reads the chart, reads the protocol, and shows its work on every single criterion, never one opaque number.
Two streams of unstructured text, the patient's record and the trial's protocol, are made structured, compared criterion by criterion, then ranked. Every step is traceable end to end.
Trial matching only earns a clinician's trust when every verdict is shown. A score they cannot interrogate is a score they will not act on, so Penetrance shows its work, always, back to the source.
Every cancer patient screened against every trial they could qualify for.
Trial matching clinicians trust, shown, sourced, reproducible.
Built by a senior data scientist with seven years across machine learning, deep learning, and AI for medicine, working directly with cancer-center trial offices.
We are onboarding a handful of cancer centers ahead of general availability. If you run a molecular tumor board or lead a clinical trials office, we would like to talk.